258 related articles for article (PubMed ID: 17506600)
1. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
6. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
Liu Z; Doan QV; Malin J; Leonard R
Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
[TBL] [Abstract][Full Text] [Related]
7. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
8. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
10. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
[TBL] [Abstract][Full Text] [Related]
11. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Weycker D; Li X; Figueredo J; Barron R; Tzivelekis S; Hagiwara M
Support Care Cancer; 2016 May; 24(5):2309-2316. PubMed ID: 26607482
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
[TBL] [Abstract][Full Text] [Related]
13. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
14. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
17. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
18. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
Danova M; Chiroli S; Rosti G; Doan QV
Tumori; 2009; 95(2):219-26. PubMed ID: 19579869
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
